Anti-TIM3 monoclonal antibody and chimeric antigen receptor
By designing high-affinity anti-TIM3 antibodies and chimeric antigen receptors, the problem of insufficient number and affinity of TIM3 binders in existing technologies has been solved, achieving highly efficient targeting of TIM3 and enhanced immunotherapy effects, especially reducing immunosuppression in cancer treatment.
Patent Information
- Application Number
- CN202411085071.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-01-28
- Filing Date
- 2022-01-28
- Publication Date
- 2024-11-19
AI Technical Summary
Existing TIM3-targeting systems and methods suffer from limited binding agent quantity and affinity, making it difficult to effectively treat and diagnose TIM3-related diseases.
We developed a high-affinity and specific anti-TIM3 antibody and chimeric antigen receptor that bind to TIM3 and contains specific variable heavy and light chain domains. This allows for efficient binding to TIM3 and the formation of scFv via adapter coupling. Furthermore, it binds to signal transduction domains to form chimeric proteins or bispecific killer cell adaptors for therapeutic and diagnostic purposes.
It achieves efficient binding and targeting of TIM3, enhancing the effectiveness of immunotherapy, especially in cancer treatment by reducing immunosuppression and enhancing anti-tumor immune responses.
Smart Images

Figure BDA0004984946740000061 
Figure BDA0004984946740000071
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with application date of January 28, 2022, application number 202210105428.7, and invention name “Anti-TIM3 Monoclonal Antibodies and Chimeric Antigen Receptors”.
[0002] Sequence Listing
[0003] The contents of the sequence listing in xml format, entitled PP243419FD.240808.sequencelisting.A20, of 80KB in size, created on August 8, 2024 and submitted electronically with this application, are incorporated by reference in their entirety. Technical Field
[0004] The field of the invention is target-specific binding molecules, and in particular relates to antibodies and chimeric antigen receptors and derivatives thereof having binding specificity for T-cell immunoglobulin mucin receptor 3 (TIM3). Background Art
[0005] The Background Description includes information that may be useful in understanding the present invention. No admission is made that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is an admission made that any publication specifically or implicitly referenced is prior art.
[0006] All publications and patent applications are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0007] T cell immunoglobulin mucin receptor 3 (TIM3) is a cell surface receptor involved in regulating innate and adaptive immune responses and is generally known to play an inhibitory function. However, some reports have also proposed stimulatory functions, which may be affected by the cell environment and / or the corresponding ligand. Most typically, TIM3 regulates macrophage activation, inhibits autoimmunity and alloimmune responses mediated by T helper type 1 lymphocytes (Th1), and promotes immune tolerance. TIM3 function is also strongly affected by the type of cell in which it is expressed. For example, in CD8+ cells, TIM3, in particular, weakens TCR-induced signal transduction by blocking NF-κB and NFAT promoter activity, thereby causing the loss of IL-2 secretion. TIM3 expressed on Treg cells can inhibit Th17 cell responses. TIM3 expressed on dendritic cells (DC) positively regulates innate immune responses and promotes the secretion of TNF-α in collaboration with Toll-like receptors. On the other hand, in tumor-infiltrating DCs, TIM3 inhibits nucleic acid-mediated innate immune responses by interacting with HMGB1 and interfering with nucleic acid-sensing and nucleic acid trafficking to endosomes.
[0008] The increasing recognition of the role of TIM3 has led to the development of various TIM3 targeting molecules. For example, WO 2019 / 140229 and WO 2016 / 144803 teach specific anti-TIM3 antibodies, and WO 2019143607 A1 describes selected treatment methods using anti-TIM3 antibodies. In other examples, as described in EP 3585403, chimeric antigen receptor (CAR) polypeptides are expressed in immune effector cells such as T cells or natural killer (NK) cells and used for adoptive cell transfer to target and kill cancers expressing TIM3. Further studies reported that anti-TIM3 antibodies promoted T cell IFN-γ-mediated anti-tumor immunity and inhibited established tumors, as discussed in Cancer Res. 2011 May 15; 71(10):3540-51; doi:10.1158 / 0008-5472, and the prospects of TIM3-targeted anti-tumor immunotherapy were discussed in Cancer Res. 2011 Nov 1; 71(21):6567-71. doi:10.1158 / 0008-547. Although such compositions and methods advantageously open up at least some TIM3-specific therapeutic approaches, the number and affinity of TIM3 binders are relatively limited.
[0009] Therefore, even though various TIM3 targeting systems and methods are known in the art, all or almost all of these systems and methods have several disadvantages. Therefore, there is still a need for compositions and methods for new and improved TIM3-specific therapeutic and diagnostic molecules. Summary of the invention
[0010] The present subject matter relates to various compositions and methods of TIM3-specific therapeutic and diagnostic molecules and their use in the diagnosis and treatment of individuals.
[0011] In one aspect of the inventive subject matter, the inventors contemplate an isolated antibody or fragment thereof, wherein the antibody or fragment thereof binds to T-cell immunoglobulin mucin receptor 3 (TIM3) and comprises a variable heavy chain (VH) domain and a variable light chain (VL) domain, wherein the VH domain is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 11, and wherein the VL domain is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12.
[0012] In one embodiment, the antibody or fragment comprises VH64-6 (SEQ ID NO: 1) and VL64-6 (SEQ ID NO: 2), optionally coupled together by a linker to form an scFv. In another embodiment, the antibody or fragment comprises VH64-15 (SEQ ID NO: 3) and VL64-15 (SEQ ID NO: 4), optionally coupled together by a linker to form an scFv. In another embodiment, the antibody or fragment comprises VH64-31 (SEQ ID NO: 5) and VL64-31 (SEQ ID NO: 6), optionally coupled together by a linker to form an scFv. In yet another embodiment, the antibody or fragment comprises VH64-32 (SEQ ID NO: 7) and VL64-32 (SEQ ID NO: 8), optionally coupled together by a linker to form an scFv. In yet another embodiment, the antibody or fragment comprises VH64-39 (SEQ ID NO: 9) and VL64-39 (SEQ ID NO: 10), optionally coupled together by a linker to form an scFv. In yet another embodiment, the antibody or fragment comprises VH66-6 (SEQ ID NO: 11) and VL66-6 (SEQ ID NO: 12), optionally coupled together by a linker to form an scFv.
[0013] Most typically, but not necessarily, the antibody is an IgG1 antibody or scFv, and / or may further comprise a therapeutic agent (e.g., a chemotherapeutic drug, a radionuclide, or an immunostimulatory agent such as a cytokine, a cytokine analog, a chemokine, or a checkpoint inhibitor). Alternatively, or in addition, the antibody or fragment may also comprise a detectable label.
[0014] In other embodiments, the inventors also contemplate chimeric proteins comprising antibodies or fragments provided herein. For example, the chimeric protein may form a chimeric antigen receptor (CAR), which may have a CD3zeta (CD3ζ) or Fc receptor ε (FcεRIγ) signaling domain, or may have a CD28 signaling domain, a 4-1BB signaling domain, and one or more of the CD3zeta (CD3ζ) signaling domain. Most typically, the CAR may have a CD8 hinge domain and a CD28 transmembrane domain. It will be readily understood that the CAR will be a recombinant CAR expressed on the surface of NK cells or cytotoxic T cells and presented on the surface. In other examples, the chimeric protein may form a bispecific fusion protein (e.g., comprising an IgG Fc portion, and optionally further comprising at least one of an IL15α receptor portion, an IL15 portion, and an IL15 superagonist portion) or may form a bispecific killer cell adapter (BiKE) or a trispecific killer cell adapter (TriKe).
[0015] Therefore, the inventors also contemplate recombinant nucleic acids encoding the isolated antibodies or fragments or chimeric proteins provided herein. For example, the nucleic acid can be a part of an expression vector or a part of a recombinant viral genome or can be in the form of linear DNA. On the other hand, the recombinant nucleic acid can also be RNA.
[0016] From a different perspective, the inventors also contemplate a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with an isolated antibody or fragment or chimeric protein as provided herein. Similarly, the inventors also contemplate a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a recombinant nucleic acid as provided herein.
[0017] In another aspect of the subject matter of the present invention, the inventors also provide a method for treating an individual, wherein the pharmaceutical composition provided herein is administered to the individual, typically thereby reducing the immunosuppression of the individual. Most typically, the individual is treated with a cancer vaccine and / or a checkpoint inhibitor. Therefore, the inventors also contemplate the use of a pharmaceutical composition as provided herein in treating individual cancers.
[0018]
[0011] Various objects, features, aspects, and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments. DETAILED DESCRIPTION
[0019] The present inventors have discovered various anti-TIM3 antibodies with high affinity and specificity for binding to TIM3. In a particularly preferred aspect, the antibody under consideration is one having a V as shown below H and V L However, it should be understood that the sequences provided herein may vary to at least some extent and thus may have one or more amino acid substitutions, insertions and / or deletions, as discussed in more detail below. Most typically, but not necessarily, V sequences with the same preceding number (e.g., 64-6) H and V L Domains or heavy and light chains will be present in a TIM3 binding construct. However, other TIM3 binding constructs may have only V H or V L domain, or a different V in the first number H and V L In addition, the TIM3 binding construct may include at least some of the CDRs listed below (e.g., at least from V H domains) of those CDRs.
[0020] 64-6V H Domain amino acid sequence:
[0021] EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMHWVRQAPGKGLEWVSAI SGSGGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRHWVLSAFDV WGQGTLVTVSS(SEQ ID NO:1)
[0022] 64-6V L Domain amino acid sequence:
[0023] DIQMTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDTFPFTFGQGTKVEIK(SEQ ID NO:2)
[0024] 64-15V H Domain amino acid sequence:
[0025] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMHWVRQAPGKGLEWVSGI SGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRGAWPFTRVVA FDVWGQGTLVTVSS(SEQ ID NO:3)
[0026] 64-15V L Domain amino acid sequence:
[0027] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQWTALPLTFGQGTKVEIK(SEQ ID NO:4)
[0028] 64-31V H Domain amino acid sequence:
[0029] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMHWVRQAPGKGLEWVS AINGNGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLTRTVPFAFD VWGQGTLVTVSS(SEQ ID NO:5)
[0030] 64-31V L Domain amino acid sequence:
[0031] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQATGWPFTFGQGTKVEIK(SEQ ID NO:6)
[0032] 64-32V H Domain amino acid sequence:
[0033] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSKYAMHWVRQAPGKGLEWVS AISGSGGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDFRIVGFDV WGQGTLVTVSS(SEQ ID NO:7)
[0034] 64-32V L Domain amino acid sequence:
[0035] DIQMTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFNTVPLTFGQGTKVEIK(SEQ ID NO:8)
[0036] 64-39V H Domain amino acid sequence:
[0037] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMHWVRQAPGKGLEWVS GISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYRVSGFD VWGQGTLVTVSS(SEQ ID NO:9)
[0038] 64-39V L Domain amino acid sequence:
[0039] DIQMTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFYSVPLTFGQGTKVEIK(SEQ ID NO:10)
[0040] 66-6V H Domain amino acid sequence:
[0041] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSKYAMHWVRQAPGKGLEWVS AISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYRFSGFDV WGQGTLVTVSS(SEQ ID NO:11)
[0042] 66-6V L Domain amino acid sequence:
[0043] DIQMTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFAAIPLTFGQGTKVEIK(SEQ ID NO:12)
[0044] It will be easy to understand that V H and V L The binding specificity of the domains is determined by their respective CDR regions and is shown in Table 1 below. H and V L Therefore, based on the known CDR sequences, it is contemplated that antibodies and fragments thereof that bind to TIM3 and include at least some of the CDRs of SEQ ID Nos: 25-60 can be prepared.
[0045] Table 1
[0046]
[0047]
[0048] For example, using the CDR above and V H and V L Domain information, IgG1 antibodies with the following exemplary heavy chain (HC) and light chain (LC) sequences can be prepared, and these heavy chain and light chain sequences have the amino acid sequences of SEQ ID No: 13-24. Most typically, but not necessarily, HC and LC with the same preceding numbers (e.g., 64-6) will be present in TIM3 binding antibodies. However, other TIM3 binding antibodies may have heavy chains and light chains with different preceding numbers.
[0049] 64-6HC amino acid sequence:
[0050] EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMHWVRQAPGKGLEWVSAISGSGGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRHWVLSAFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:13)
[0051] 64 - 6LC amino acid sequence:
[0052] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDTFPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:14)
[0053] 64 - 15HC amino acid sequence:
[0054] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMHWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRGAWPFTRVVAFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:15)
[0055] 64 - 15 LC amino acid sequence:
[0056] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQWTALPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:16)
[0057] 64 - 31 HC amino acid sequence:
[0058] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMHWVRQAPGKGLEWVSAINGNGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLTRTVPFAFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:17)
[0059] 64 - 31 LC amino acid sequence:
[0060] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQATGWPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:18)
[0061] 64 - 32 HC amino acid sequence:
[0062] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSKYAMHWVRQAPGKGLEWVSAISGSGGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDFRIVGFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:19)
[0063] 64 - 32 LC amino acid sequence:
[0064] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFNTVPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:20)
[0065] 64 - 39 HC amino acid sequence:
[0066] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMHWVRQAPGKGLEWVSGISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYRVSGFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:21)
[0067] 64 - 39 LC amino acid sequence:
[0068] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFYSVPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:22)
[0069] 66 - 6HC amino acid sequence:
[0070] MEVQLVESGGGLVQPGGSLRLSCAASGFTFSKYAMHWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYRFSGFDVWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:23)
[0071] 66-6LC amino acid sequence:
[0072] DIQMTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFAAIPLTFGQGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:24)
[0073] In a typical example, the inventors prepared antibodies using the above HC and LC sequences with matching preceding numbers and tested the TIM3 binding of the antibodies so prepared. Table 2 describes exemplary results for determining antibody dissociation constants. More specifically, K was measured by SPR (Pioneer FE) or Octet (Red96e) at 25°C or 37°C. D Determination. All values are x 10 -9M. Anti-TIM-3 IgG1 antibody was captured on the chip surface using anti-human Fc antibody (SPR) or AHC sensor (Octet), and human TIM-3 was the analyte.
[0074] Table 2
[0075] aTIM-3IgG1 25℃ 37℃ 64-6 0.46 2.50 64-15 0.71 5.40 64-31 10.4 36.5 64-32 0.39 0.92 64-39 1.53 6.39 66-6 1.69 7.01
[0076] It is noteworthy that despite being the same type of antibody (here IgG1) with otherwise identical framework regions, the antibodies tested exhibit unexpected differences in affinity that span almost three orders of magnitude, as can be seen from Table 2 above. Here, antibodies 64-6, 64-15 and 64-32 have subnanomolar K values at 25°C. D values, while antibodies 64-39 and 66-6 have single-digit K values at 25 °C. D values, and antibody 64-31 has a double-digit K at 25 °C D Similarly, for antibodies 64-32 and 64-31, the K values of each antibody between 25°C and 37°C were D The difference is unexpectedly low (2.36x and 3.51), while antibodies 64-6, 64-39 and 66-6 are higher (5.43x, 4.18x, 4.15x), and antibody 64-15 is even higher (7.61x). From a different perspective, the affinity of antibodies 64-6 and 64-32 for TIM-3 at physiological temperature is two orders of magnitude stronger than that of antibody 64-31.
[0077] Of course, it should be understood that the subject matter of the present invention is not limited to the exact sequence described above, but one or more sequences may include one or more amino acid changes. Most preferably, these changes will not result in a significant reduction in specificity and / or affinity. Thus, the amino acid changes contemplated will typically be within V H and / or V L In the framework region of the structural domain, and / or in the constant region of the HC and / or LC. From a different perspective, the amino acid changes will preferably not be present in the CDR region. For example, the sequence under consideration will have 98%-99% identity or homology, or 96%-98% identity or homology, or 92%-96% identity or homology, or 85%-92% identity or homology, or 75%-85% identity or homology, most typically (but not necessarily) the changed amino acid is outside the CDR. In other options for amino acid changes, one or more amino acids can be changed to "humanize" non-human antibodies, and / or move or eliminate one or more glycosylation sites.
[0078] In addition, it should be noted that the antibodies considered will explicitly include various forms such as monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, single domain antibodies, single chain Fv (scFv), single chain antibodies, disulfide bond-linked Fv (sdFv), BiKe and TriKe, as described in more detail below. Of course, it should also be noted that the term antibody explicitly includes all classes of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, IgA and IgY) and the corresponding subclasses (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2).
[0079] With respect to antibody fragments contemplated, it should be noted that a fragment will include the CDRs (typically V H and V L All CDRs of at least one of the above) and one or more parts of the optional framework residues. Therefore, the antibody fragment will show the ability to specifically bind to the antigen (here, the epitope of TIM3) in most cases. Among other fragments, the fragments considered in particular include Fab', F(ab')2, Fv, scFv and mutants thereof, naturally occurring variants, and fusion proteins with various non-antibody polypeptides (e.g., toxins, antigen recognition sites of different antigens, enzymes, receptors, receptor ligands, etc.). From a different perspective, the antibody fragment considered will have at least 20 continuous amino acid residues, at least 25 continuous amino acid residues, at least 40 continuous amino acid residues, at least 50 continuous amino acid residues, at least 60 continuous amino acid residues, at least 70 continuous amino acid residues, at least 80 continuous amino acid residues, at least 90 continuous amino acid residues, at least 100 continuous amino acid residues, at least 125 continuous amino acid residues, at least 150 continuous amino acid residues, at least 175 continuous amino acid residues, at least 200 continuous amino acid residues or at least 250 continuous amino acid residues.
[0080] In further consideration, the antibody or its fragment can be used for in vitro or in vivo diagnosis, and is therefore coupled to a detectable label. For example, suitable detectable labels include various enzymes, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals and non-radioactive paramagnetic metal ions. The detectable label can be directly coupled or conjugated to the antibody using techniques known in the art or indirectly coupled or conjugated to the antibody through an intermediate (e.g., a chemical or biological linker). Additionally or alternatively, the antibody and its fragment considered can also be coupled to a solid support, which is particularly useful for immunoassays or purification of TIM3 or cells expressing TIM3. For example, suitable supports include magnetic beads, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride and polypropylene.
[0081] The antibody and its fragment considered can also be coupled or include a therapeutic agent to target the therapeutic agent to cells expressing TIM3. For example, the therapeutic agent specifically considered includes chemotherapeutics, radionuclides and immunostimulants (such as cytokines, cytokine analogs, chemokines or checkpoint inhibitors). There are many ways to prepare antibody-drug conjugates, and all of these are considered to be applicable to this article.
[0082] In particularly preferred aspects, the antibody or fragment thereof under consideration can also be prepared as a chimeric protein, wherein at least a portion of the antibody is continuous with a second polypeptide (optionally via a preferably flexible linker). For example, a suitable chimeric protein can be constructed as a chimeric antigen receptor (CAR), which can have an intracellular signaling portion, a transmembrane portion, and an extracellular recognition domain. In this case, it is generally considered that the recognition domain includes an antibody fragment (e.g., scFv or a single domain) and / or the intracellular signaling domain includes an activation / ITAM motif. In other options, it may be considered that the first, second, or third generation CARs have a variety of domains known in the art. For example, a suitable CAR will include a CD8 hinge portion, a CD28 transmembrane domain, and a CD3zeta (CD3ζ) or Fc receptor ε (FcεRIγ) signaling domain. Alternatively, the signaling domain may also include one or more of a CD28 signaling domain, a 4-1BB signaling domain, and a CD3zeta (CD3ζ) signaling domain. In other options, such chimeric antigen receptors are preferably expressed in cytotoxic immune competent cells, particularly NK cells and / or T cells.
[0083] On the other hand, especially when anti-TIM3 antibodies or fragments thereof are used to further mediate cell or receptor / ligand contact, the chimeric protein under consideration can be constructed as a bispecific fusion protein, a bispecific killer cell adapter (BiKE) or a trispecific killer cell adapter (TriKe). For example, a bispecific fusion protein may include an anti-TIM3 antibody or a portion thereof and a second affinity ligand that selectively binds to a desired target. This target may be a soluble protein or a cell-binding protein, and targets particularly contemplated include PD-L1. On the other hand, the chimeric molecule under consideration may be constructed as a bispecific polypeptide (e.g., a first scFv coupled to a second scFv by a linker), wherein a portion thereof includes an anti-TIM3 antibody or a portion thereof, and wherein another portion thereof has a binder for an immune-competent cell-specific marker (e.g., anti-CD3).
[0084] In further contemplated aspects, anti-TIM3 antibodies or portions thereof may also be coupled to IgG-Fc / IL15Rα / IL15 hybrids (e.g., ALT803). For example, an anti-TIM3 antibody fragment may be a scFv portion coupled to one or both arms of the hybrid to form a TxM (see URL: TxM technology at Altorbioscience.com). Alternatively, an anti-TIM3 antibody fragment may be a scFv portion coupled to one arm of the hybrid, while the other arm of the hybrid may be a scFv portion that binds to PD-L1 (or other immune-related ligands).
[0085] It should be understood that nucleic acids encoding the anti-TIM3 antibodies considered are also explicitly contemplated herein, and that a technician will be able to easily prepare such nucleic acids (e.g., DNA, RNA) and recombinant entities comprising such nucleic acids. In other options, suitable recombinant entities include yeast, bacterial and viral expression vectors, linear DNA, RNA, etc. for genome editing or other integration. Of course, it should be recognized that recombinant nucleic acids will include suitable regulatory elements to allow expression of recombinant constructs. In addition, it should be noted that with respect to host cells containing and expressing recombinant nucleic acids, nucleic acids will generally be optimized using codons.
[0086] It will be readily appreciated that the use of anti-TIM3 antibodies, fragments thereof, or chimeric proteins comprising anti-TIM3 antibodies or fragments thereof is particularly advantageous in the case of reducing or inhibiting immunosuppression mediated by TIM3. Thus, antibodies or portions thereof can be particularly useful for reversing or reducing immunosuppression by TIM3 signaling. In addition, when cancer cells express and display TIM3, the cells can provide additional therapeutic targets (e.g., by targeting with a chimeric molecule having a TIM3 binding portion and an immunostimulatory portion (e.g., ALT-803)).
[0087] In view of these findings, the inventors also consider the use of various recombinant TIM3 binding molecules such as antibodies and fragments thereof, and cells expressing anti-TIM3 CAR molecules and pharmaceutical compositions containing them. Most typically, such recombinant proteins can be soluble forms of antibodies and fragments thereof, soluble chimeric molecules comprising TIM3 binding portions, or membrane-bound molecules such as CARs comprising TIM3 binding portions. For example, recombinant TIM3 binding CARs can be expressed in cytotoxic cells such as T cells, natural killer cells, or NKT cells.
[0088] It is contemplated that the pharmaceutical compositions thus prepared or produced can be administered to patients with tumors to enhance the effectiveness of immunotherapy to treat tumors (e.g., modulate (e.g., reduce, eliminate, etc.) tumor immunosuppression, reduce tumor size, etc.). In some embodiments, the pharmaceutical composition and / or tumor vaccine can be administered by systemic injection, including subcutaneous (subdermal) injection or intravenous injection. In other embodiments, when systemic injection may not be effective (e.g., for brain tumors, etc.) or more localized treatment is required, it is contemplated that the recombinant immunoglobulin complex and / or pharmaceutical composition can be administered by intratumoral injection. As used herein, the term "administering" refers to direct and indirect administration of the compounds and compositions contemplated herein, wherein direct administration is typically performed by a healthcare professional (e.g., a physician, nurse, etc.), and indirect administration typically includes steps of providing or preparing compounds and compositions available to a healthcare professional for direct administration.
[0089] Regarding the dosage and schedule of administration, it is contemplated that the dosage and / or schedule may vary depending on the type of protein, protein complex, or pharmaceutical composition (e.g., virus, bacteria, yeast in combination with a recombinant protein complex, etc.), the type and prognosis of the disease (e.g., tumor type, size, location), and the patient's health status (e.g., including age, sex, etc.). Although the dosage and schedule may vary, the dosage and schedule may be selected and adjusted so that the formulation does not produce any significant toxic effects on normal cells of the host, but is sufficient to reduce immunosuppression by reducing T cell differentiation and / or activation in the tumor microenvironment. Therefore, in a preferred embodiment, the optimal or desired conditions for administering the formulation may be determined based on a predetermined threshold. For example, the predetermined threshold may be a predetermined local or systemic concentration of a cytokine (e.g., IL-2, IL-12, IFN-γ, IL-12, IL-23, IL-1b, IL-6, or TGF-β, etc.) released by T cells in the tumor microenvironment. Therefore, the application conditions are usually adjusted so that one or more of these cytokines increase in the tumor microenvironment by at least 20%, at least 30%, at least 50%, at least 60%, at least 70% for at least 24 hours, 48 hours, 72 hours, 7 days, etc. In addition, it is contemplated that the compounds and compositions provided herein can be co-administered with NK cells (simultaneously or sequentially). For example, suitable NK cells include autologous NK cells and NK92 cells and derivatives thereof (e.g., aNK cells, haNK cells, taNK cells, all of which can be commercially available from NantKwest, 9920 Jefferson Blvd. Culver City, CA, 90232).
[0090] In some embodiments, the digits of the amount of the expression composition, characteristic (such as concentration), reaction conditions, etc., used to describe and claim certain embodiments of the present invention should be understood to be modified by the term "about" in some cases. Therefore, in some embodiments, the numerical parameters listed in the written specification and the appended claims are approximate values, which can vary according to the desired characteristics that a particular embodiment attempts to obtain. The description of the range of values herein is intended only to be used as a shorthand method for individually referring to each individual value falling within the range. Unless otherwise stated in this article, each individual value is incorporated into the specification as if it were individually quoted in this article.
[0091] As used herein, the term "administering" a pharmaceutical composition or drug refers to both direct and indirect administration of a pharmaceutical composition or drug, wherein direct administration of a pharmaceutical composition or drug is typically performed by a health care professional (e.g., a physician, nurse, etc.), and wherein indirect administration includes the step of providing the pharmaceutical composition or drug to or making available to a health care professional for direct administration (e.g., via injection, infusion, oral delivery, topical delivery, etc.). It should also be noted that the term "prognosis" or "prediction" of a condition, susceptibility to disease development, or response to a desired treatment is intended to encompass the act of predicting or predicting a condition, susceptibility, and / or response (including the rate of progression, improvement, and / or duration of a condition in a subject) (but not the act of treating or diagnosing).
[0092] Unless otherwise indicated herein or otherwise clearly contradictory to the context, all methods described herein can be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "such as") provided with respect to certain embodiments herein is intended only to better illustrate the present invention, without limiting the scope of the present invention as originally claimed. Any language in this specification should not be interpreted as indicating that any unclaimed element is necessary to practice the present invention.
[0093] As used in the specification herein and throughout the claims that follow, the meanings of "a", "an", and "the" include plural references unless the context clearly indicates otherwise. Moreover, as used in the specification herein, the meaning of "in" includes "in" and "on", unless the context clearly indicates otherwise. Also as used herein, and unless the context indicates otherwise, the term "coupled to" is intended to include direct coupling (where two elements coupled to each other are in contact with each other) and indirect coupling (where at least one additional element is located between the two elements). Therefore, the terms "coupled to" and "coupled with" are used synonymously.
[0094] It should be clear to those skilled in the art that more modifications other than those described are possible without departing from the inventive concept of this article. Therefore, the subject matter of the present invention is limited only to the scope of the appended claims. In addition, when interpreting this specification and claims, all terms should be interpreted in a manner as broad as possible consistent with the context. In particular, the term "comprises" and "comprising" should be interpreted as referring to elements, components or steps in a non-exclusive manner, thereby indicating that the mentioned elements, components or steps can exist, or use, or combine with other elements, components or steps not explicitly mentioned. In the case of at least one of something selected from the group consisting of A, B, C ... and N in the claims of this specification, the text should be interpreted as requiring only one element in the group, rather than A plus N or B plus N, etc.
Claims
1. A chimeric protein comprising a first domain and a second domain, wherein the first domain comprises at least one of IL15Rα and IL15 and the second domain comprises an antibody or a binding fragment thereof, wherein the antibody or the binding fragment thereof binds to T-cell immunoglobulin mucin receptor 3 (TIM3), the antibody or the binding fragment thereof comprising: a variable heavy chain (VH) domain and a variable light chain (VL) domain; and wherein the antibody or fragment thereof comprises a VH domain and a VL domain consisting of SEQ ID NO: 1 and SEQ ID NO: 2, consisting of SEQ ID NO: 3 and SEQ ID NO: 4, consisting of SEQ ID NO: 7 and SEQ ID NO: 8, consisting of SEQ ID NO: 9 and SEQ ID NO: 10, or consisting of SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
2. The chimeric protein of claim 1, wherein the VH domain and the VL domain are optionally coupled together via a linker to form an scFv. The chimeric protein of claim 1 , wherein the antibody is an IgG1 antibody.
4. The chimeric protein of claim 1, further comprising a therapeutic agent or a detectable label.
5. The chimeric protein of claim 4, wherein the therapeutic agent is a chemotherapeutic drug, a radionuclide, or an immunostimulatory agent selected from the group consisting of a cytokine, a cytokine analog, and a checkpoint inhibitor. The chimeric protein of claim 5 , wherein the cytokine is a chemokine.
7. The chimeric protein of claim 1, wherein the chimeric protein is a bispecific fusion protein.
8. The chimeric protein of claim 7, wherein the bispecific fusion protein comprises an IgG Fc domain.
9. The chimeric protein according to claim 7, which is constructed as a bispecific killer cell engager (BiKE) or a trispecific killer cell engager (TriKe).
10. A recombinant nucleic acid encoding the chimeric protein according to any one of claims 1 to 9.
11. The recombinant nucleic acid according to claim 10, wherein the nucleic acid is in an expression vector or in a recombinant viral genome, or in the form of linear DNA.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with the chimeric protein according to any one of claims 1-9.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with the recombinant nucleic acid according to any one of claims 10-11.
14. A chimeric protein comprising a bispecific fusion protein, the bispecific fusion protein comprising a first domain and a second domain, the first domain comprising a first binding domain, the second domain comprising a second binding domain, the second binding domain comprising an antibody or a binding fragment thereof, wherein the antibody or the binding fragment thereof binds to T-cell immunoglobulin mucin receptor 3 (TIM3), the antibody or the binding fragment thereof comprising: a variable heavy chain (VH) domain and a variable light chain (VL) domain; and wherein the antibody or fragment thereof comprises a VH domain and a VL domain consisting of SEQ ID NO: 1 and SEQ ID NO: 2, consisting of SEQ ID NO: 3 and SEQ ID NO: 4, consisting of SEQ ID NO: 7 and SEQ ID NO: 8, consisting of SEQ ID NO: 9 and SEQ ID NO: 10, or consisting of SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
15. The chimeric protein of claim 14, wherein the first binding domain has a specific affinity for a check point inhibitor.
16. The chimeric protein of claim 15, wherein the first binding domain has a specific affinity for PD-L1.
17. The chimeric protein of claim 14, wherein the first binding domain has a specific affinity for immune competent cells.
18. The chimeric protein of claim 14, wherein the first binding domain has specific affinity for a tumor antigen.
19. The chimeric protein of claim 14, wherein the first binding domain comprises scFv.
20. The chimeric protein of claim 18, wherein the second binding domain comprises a scFv.
21. The chimeric protein of claim 19, wherein the first binding domain and the second binding domain are connected by a linker.
22. The chimeric protein of claim 14, wherein the bispecific fusion protein comprises an IgG Fc domain.
23. The chimeric protein of claim 14, which is constructed as a bispecific killer cell engager (BiKE) or a trispecific killer cell engager (TriKe).
24. The chimeric protein of claim 22, wherein the bispecific fusion protein comprises at least one of IL15Rα and IL15.
25. A recombinant nucleic acid encoding the chimeric protein according to any one of claims 14-24.
26. The recombinant nucleic acid according to claim 25, wherein the nucleic acid is in an expression vector or in a recombinant viral genome, or in the form of linear DNA.
27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with the chimeric protein of any one of claims 14-24.
28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with the recombinant nucleic acid according to any one of claims 25-26.
29. Use of a pharmaceutical composition in the preparation of a medicament for treating cancer, the composition comprising an isolated antibody or fragment thereof, wherein the antibody or fragment thereof binds to T-cell immunoglobulin mucin receptor 3 (TIM3), the antibody or fragment thereof comprising: a variable heavy chain (VH) domain and a variable light chain (VL) domain; and wherein the antibody or fragment thereof comprises a VH domain and a VL domain consisting of SEQ ID NO: 1 and SEQ ID NO: 2, consisting of SEQ ID NO: 3 and SEQ ID NO: 4, consisting of SEQ ID NO: 7 and SEQ ID NO: 8, consisting of SEQ ID NO: 9 and SEQ ID NO: 10, or consisting of SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
30. The use according to claim 29, wherein the drug is administered by subcutaneous injection, dermal injection, intravenous injection or intratumoral injection.
31. The use according to claim 29, wherein the medicament is administered together with a cancer vaccine.
32. The use according to claim 29, wherein the medicament is administered together with a checkpoint inhibitor.
33. Use of a pharmaceutical composition in the preparation of a medicament for reducing immunosuppression in a patient, the composition comprising an isolated antibody or fragment thereof, wherein the antibody or fragment thereof binds to T-cell immunoglobulin mucin receptor 3 (TIM3), the antibody or fragment thereof comprising: a variable heavy chain (VH) domain and a variable light chain (VL) domain; and wherein the antibody or fragment thereof comprises a VH domain and a VL domain consisting of SEQ ID NO: 1 and SEQ ID NO: 2, consisting of SEQ ID NO: 3 and SEQ ID NO: 4, consisting of SEQ ID NO: 7 and SEQ ID NO: 8, consisting of SEQ ID NO: 9 and SEQ ID NO: 10, or consisting of SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
34. The use according to claim 33, wherein the drug is administered by subcutaneous injection, dermal injection, intravenous injection or intratumoral injection.
35. The use according to claim 33, wherein the medicament is administered together with a cancer vaccine.
36. The use according to claim 33, wherein the medicament is administered together with a checkpoint inhibitor.
Citation Information
Patent Citations
Antibodies against tim3 and uses thereof
WO2019140229A1
Methods of treating cancer with antibodies against tim3
WO2019143607A1
